HEMLIBRA
@hemlibra-hcp.com
Discover FDA approved HEMLIBRA® (emicizumab-kxwh) for prophylactic treatment in hemophilia A patients with or without factor VIII inhibitors. See BOXED WARNING.
HEMLIBRA's Company Logos
HEMLIBRA's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#F04E2A
Flamingo
240, 78, 42
11, 87, 55
0, 68, 83, 6
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#333333
Mine Shaft
51, 51, 51
0, 0, 20
0, 0, 0, 80
About HEMLIBRA
HEMLIBRA® (emicizumab-kxwh) is a pioneering medication developed by Genentech, designed for the prophylactic treatment of hemophilia A in patients, both with and without factor VIII inhibitors. FDA approved and widely recognized as the #1 prescribed prophylaxis for hemophilia A, HEMLIBRA offers patients a flexible solution with six different vial options to accommodate varied patient needs. Its unique pharmacokinetics feature a half-life measured in weeks, allowing for more effective management of bleeding episodes in both adults and pediatric patients.
In addition to treatment, Genentech prioritizes patient support through various resources, including financial assistance and educational materials for both patients and caregivers. HEMLIBRA's extensive clinical trial data underscores its efficacy and safety profile, while ongoing monitoring and support ensure optimal patient outcomes. The brand continues to focus on delivering innovative solutions and comprehensive resources to empower hemophilia A patients in their journey towards improved health and quality of life.
Brand industry
Health
Company type
Suggest company type
Year founded
Suggest founded year
Company size
Suggest company size
